Related Experiment Videos
Protein chip array profiling analysis of sera from neuroblastoma patients
Valérie Combaret1, Christophe Bergeron, Stéphanie Bréjon
1Centre Léon Bérard, Unité d'Oncologie Moléculaire, 28 rue Laënnec 69008 LYON France, Université Claude Bernard Lyon I, 8 avenue Rockefeller 69008, Lyon, France.
Cancer Letters
|June 1, 2005
Summary
Researchers identified a serum biomarker, Serum Amyloid A (SAA) protein, that predicts prognosis in neuroblastoma, a common childhood cancer. This discovery offers a potential non-invasive tool for better disease monitoring and risk stratification.
Area of Science:
- Biochemistry
- Oncology
- Pediatric Medicine
Background:
- Neuroblastoma is the most common pediatric extracranial solid tumor.
- Clinical behavior is highly heterogeneous, necessitating risk stratification.
- Current prognostic markers rely on clinical and biological features, with a need for non-invasive alternatives.
Purpose of the Study:
- To identify novel, non-invasive prognostic serum biomarkers for neuroblastoma.
- To correlate biomarker levels with patient outcome independently of current risk stratification.
- To validate the identified biomarker's prognostic significance.
Main Methods:
- Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) for biomarker discovery.
- Peptide mapping for biomarker identification.
- Enzyme-linked immunosorbent assay (ELISA) for biomarker validation.
Main Results:
- SELDI-TOF-MS identified a serum biomarker strongly correlating with neuroblastoma prognosis.
- Peptide mapping identified the biomarker as Serum Amyloid A (SAA) protein.
- Elevated SAA levels, confirmed by ELISA, were associated with poor prognosis in neuroblastoma patients.
Conclusions:
- Serum Amyloid A (SAA) protein is a promising non-invasive prognostic biomarker for neuroblastoma.
- SAA levels may aid in refining risk stratification and disease monitoring.
- Further investigation into the promises and limitations of SAA as a prognostic tool is warranted.